FY2025 EPS Estimates for Medpace Raised by Leerink Partnrs

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Stock analysts at Leerink Partnrs upped their FY2025 EPS estimates for Medpace in a research note issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $12.66 per share for the year, up from their prior estimate of $12.46. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace's FY2026 earnings at $13.07 EPS and FY2027 earnings at $14.27 EPS.

A number of other brokerages have also recently commented on MEDP. Robert W. Baird cut their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Mizuho cut their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Leerink Partners initiated coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective on the stock. Barclays initiated coverage on shares of Medpace in a research report on Tuesday, June 24th. They set an "equal weight" rating and a $300.00 price objective on the stock. Finally, TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and cut their price objective for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Twelve equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Medpace presently has an average rating of "Hold" and an average price target of $344.82.

Medpace Stock Down 0.5%

MEDP traded down $1.55 during trading on Wednesday, reaching $320.95. 412,824 shares of the stock traded hands, compared to its average volume of 375,869. The stock has a market capitalization of $9.22 billion, a PE ratio of 24.50, a P/E/G ratio of 5.75 and a beta of 1.47. The stock's 50-day moving average is $304.48 and its 200 day moving average is $319.05. Medpace has a 12 month low of $250.05 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a net margin of 19.31% and a return on equity of 54.36%. The company had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. During the same quarter in the previous year, the firm posted $3.20 earnings per share.

Institutional Investors Weigh In On Medpace

Several institutional investors and hedge funds have recently added to or reduced their stakes in MEDP. Mawer Investment Management Ltd. purchased a new stake in Medpace in the 1st quarter valued at about $212,131,000. Invesco Ltd. increased its stake in Medpace by 91.8% in the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after buying an additional 519,186 shares during the last quarter. Vulcan Value Partners LLC increased its stake in Medpace by 221.6% in the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock valued at $99,159,000 after buying an additional 224,578 shares during the last quarter. Norges Bank purchased a new stake in shares of Medpace during the 4th quarter worth approximately $69,859,000. Finally, Fundsmith LLP purchased a new stake in shares of Medpace during the 4th quarter worth approximately $42,372,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insider Buying and Selling

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director owned 2,998 shares in the company, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.